Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge

Leon de Waal; Ultan F Power; Selma Yüksel; Geert van Amerongen; Thien N Nguyen; Hubert G M Niesters; Rik L de Swart; Albert D M E Osterhaus

doi:10.1016/j.vaccine.2003.10.008

Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge

Leon de Waal, Ultan F Power, Selma Yüksel, Geert van Amerongen, Thien N Nguyen, Hubert G M Niesters, Rik L de Swart, Albert D M E Osterhaus

Onderzoeksoutput: Article › Academic › peer review

48 Citaten (Scopus)

Samenvatting

We have addressed the safety of alum-adsorbed BBG2Na, a recombinant respiratory syncytial virus (RSV) subunit vaccine, in infant macaques. Animals received two vaccinations, and were challenged 4 months later with RSV. In two of four BBG2Na-vaccinated animals, specific IL-13 producing T cells were detected. Upon challenge, low level pulmonary eosinophilia was observed in the same two animals. Although the levels of these responses were substantially lower than those observed in the FI-RSV controls, these data suggest that more extensive studies focusing on immunopathological safety of alum-adsorbed BBG2Na in non-human primates would be required before proceeding to clinical trials in seronegative infants.

Originele taal-2	English
Pagina's (van-tot)	915-22
Aantal pagina's	8
Tijdschrift	Vaccine
Volume	22
Nummer van het tijdschrift	8
DOI's	https://doi.org/10.1016/j.vaccine.2003.10.008
Status	Published - 25-feb.-2004
Extern gepubliceerd	Ja

Toegang tot document

10.1016/j.vaccine.2003.10.008

Handle.net

Permanente koppeling

Citeer dit

@article{988f4b5bdab047ea94816cee305e29d2,

title = "Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge",

abstract = "We have addressed the safety of alum-adsorbed BBG2Na, a recombinant respiratory syncytial virus (RSV) subunit vaccine, in infant macaques. Animals received two vaccinations, and were challenged 4 months later with RSV. In two of four BBG2Na-vaccinated animals, specific IL-13 producing T cells were detected. Upon challenge, low level pulmonary eosinophilia was observed in the same two animals. Although the levels of these responses were substantially lower than those observed in the FI-RSV controls, these data suggest that more extensive studies focusing on immunopathological safety of alum-adsorbed BBG2Na in non-human primates would be required before proceeding to clinical trials in seronegative infants.",

keywords = "Animals, Antibodies, Viral, Immunoglobulin G, Interleukin-13, Macaca fascicularis, Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus Vaccines, Respiratory Syncytial Viruses, Reverse Transcriptase Polymerase Chain Reaction, Time Factors, Vaccination",

author = "{de Waal}, Leon and Power, {Ultan F} and Selma Y{\"u}ksel and {van Amerongen}, Geert and Nguyen, {Thien N} and Niesters, {Hubert G M} and {de Swart}, {Rik L} and Osterhaus, {Albert D M E}",

year = "2004",

month = feb,

day = "25",

doi = "10.1016/j.vaccine.2003.10.008",

language = "English",

volume = "22",

pages = "915--22",

journal = "Vaccine",

issn = "0264-410X",

publisher = "ELSEVIER SCI LTD",

number = "8",

}

TY - JOUR

T1 - Evaluation of BBG2Na in infant macaques

T2 - specific immune responses after vaccination and RSV challenge

AU - de Waal, Leon

AU - Power, Ultan F

AU - Yüksel, Selma

AU - van Amerongen, Geert

AU - Nguyen, Thien N

AU - Niesters, Hubert G M

AU - de Swart, Rik L

AU - Osterhaus, Albert D M E

PY - 2004/2/25

Y1 - 2004/2/25

N2 - We have addressed the safety of alum-adsorbed BBG2Na, a recombinant respiratory syncytial virus (RSV) subunit vaccine, in infant macaques. Animals received two vaccinations, and were challenged 4 months later with RSV. In two of four BBG2Na-vaccinated animals, specific IL-13 producing T cells were detected. Upon challenge, low level pulmonary eosinophilia was observed in the same two animals. Although the levels of these responses were substantially lower than those observed in the FI-RSV controls, these data suggest that more extensive studies focusing on immunopathological safety of alum-adsorbed BBG2Na in non-human primates would be required before proceeding to clinical trials in seronegative infants.

AB - We have addressed the safety of alum-adsorbed BBG2Na, a recombinant respiratory syncytial virus (RSV) subunit vaccine, in infant macaques. Animals received two vaccinations, and were challenged 4 months later with RSV. In two of four BBG2Na-vaccinated animals, specific IL-13 producing T cells were detected. Upon challenge, low level pulmonary eosinophilia was observed in the same two animals. Although the levels of these responses were substantially lower than those observed in the FI-RSV controls, these data suggest that more extensive studies focusing on immunopathological safety of alum-adsorbed BBG2Na in non-human primates would be required before proceeding to clinical trials in seronegative infants.

KW - Animals

KW - Antibodies, Viral

KW - Immunoglobulin G

KW - Interleukin-13

KW - Macaca fascicularis

KW - Respiratory Syncytial Virus Infections

KW - Respiratory Syncytial Virus Vaccines

KW - Respiratory Syncytial Viruses

KW - Reverse Transcriptase Polymerase Chain Reaction

KW - Time Factors

KW - Vaccination

U2 - 10.1016/j.vaccine.2003.10.008

DO - 10.1016/j.vaccine.2003.10.008

M3 - Article

C2 - 15161068

SN - 0264-410X

VL - 22

SP - 915

EP - 922

JO - Vaccine

JF - Vaccine

IS - 8

ER -

Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge

Samenvatting

Toegang tot document

Handle.net

Vingerafdruk

Citeer dit